-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bridalumab is a human monoclonal antibody that can bind to and block the signal mediated by the IL-17 receptor
.
This study explored the efficacy and safety of brodazumab in the treatment of axial spondyloarthritis (axSpA)
.
Bridalumab is a human monoclonal antibody that can bind to and block the signal mediated by the IL-17 receptor
This is a multi-center, placebo-controlled Phase 3 study (NCT02985983).
The axSpA patients were randomly divided into groups according to a 1:1 ratio.
This is a multi-center, placebo-controlled Phase 3 study (NCT02985983).
The results are as follows: the ASAS 40 response rate (95%CI) of the brodazumab group was 43.
8% (35/80; 32.
The results are as follows: the ASAS 40 response rate (95%CI) of the brodazumab group was 43.
Figure: Response rates of ASAS40 and ASAS20 in patients with spondyloarthritis
Figure: Response rate of ASAS40 and ASAS20 in patients with spondyloarthritis Figure: Response rate of ASAS40 and ASAS20 in patients with spondyloarthritisFor patients with active axSpA, brodazumab showed significant efficacy at the 16th week
.
For patients with active axSpA, brodazumab showed significant efficacy at the 16th week
Original source:
Original source: Original source:James Cheng-Chung Wei.
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial.
James Cheng-Chung Wei.
Leave a message here
